Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OHR/AVR118 in cancer anorexia-cachexia
NCT01206335Phase 2Unknown
- Sponsor
- Ohr Pharmaceutical, Inc.
- Start
- Sep 2010
- Primary completion
- Dec 2012
- Modality
- Peptides, Nucleic Acid Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of EOM613 in cancer cachexia, anorexia nervosa (AN), sponsored by Ohr Pharmaceutical, Inc.. Status: unknown.
02
Drugs
EOM613
03
Conditions
cancer cachexiaanorexia nervosa (AN)
Beyond the preview
Go deeper on NCT01206335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01206335.